The presentation will demonstrate safety and immunogenicity, provide an update on NIH-funded avian influenza trials, and highlight the technology’s potential in pandemic preparedness.
ANN ARBOR, Mich., Oct. 28, 2024 (Globe Newswire) — BlueWillow Biologics, Inc., a clinical-stage biotechnology company pioneering the future of intranasal vaccines, today announced that the company is a key player in the advancement of intranasal vaccines. announced that they would be announcing significant progress. World Vaccine Congress – European Candidates to be held on October 29, 2024 at 3:40 pm (GMT) at Theater 2, Fira de Barcelona Montjuic, Barcelona, Spain.
In a presentation entitled “NanoVax™ Intranasal Adjuvant Clinical Development Update: Safety and Immunogenicity,” Chad Costley, MD, MBA, President and CEO of BlueWillow, discussed the scope of data included in the company’s results. Let’s talk about expansion in detail. Current H5N1 (“bird flu”) clinical trials. Trials have already been completed and publication is expected soon. This presentation will also explore the platform’s potential to broadly transform the intranasal vaccine landscape, particularly for influenza (pandemic and seasonal), tuberculosis, COVID-19, RSV, sexually transmitted diseases, and peanut allergy.
“Given the coronavirus disease 2019 (Covid-19) pandemic and the current threat of H5N1 influenza, also known as avian influenza, we must not only protect people from symptomatic disease, but also prevent it from being contagious. We recognize the importance of developing next-generation vaccines. Vaccines administered via nasal spray show promising potential to achieve both goals while increasing public willingness to get vaccinated.” Dr. Lee said. “BlueWillow’s NanoVax™ adjuvant and antigen delivery platform is well-positioned to enable the paradigm shift needed to address urgent public health needs. I look forward to sharing my progress.”
With established human safety and immunogenicity evidence, BlueWillow’s unique platform addresses the need for next-generation vaccines that elicit superior mucosal immunity. The NanoVax® platform (“W805EC”) is compatible with a wide range of viral, bacterial, and food antigens. It triggers the triple mucosal, cellular, and systemic immune responses necessary for strong protection against both symptomatic and infectious diseases.
World Vaccine Congress Europe is Europe’s largest and most established conference on vaccine research and development. The conference will be attended by representatives from numerous government agencies, nonprofit organizations, pharmaceutical and biotechnology companies, and world-renowned academic researchers. All will meet to discuss the latest advances in vaccine development.
story continues
For more information about BlueWillow Biologics and its intranasal platform technology, please visit www.BlueWillow.com.
About Blue Willow
BlueWillow Biologics, Inc., based in Ann Arbor, Michigan, is a clinical-stage biotechnology company pioneering the future of intranasal vaccines that will transform the landscape of pandemic preparedness, infectious disease, and food allergy prevention and treatment. BlueWillow’s technology provides powerful protection against a wide range of health threats by inducing a comprehensive immune response, preventing symptomatic disease and transmission. Directed by physicians and scientists who have been successful in building life science ventures, the leadership has built numerous successful biotech ventures, with expertise in vaccine development, chemical engineering, intranasal adjuvants and antigen delivery. We combine an experienced management team. Visit www.BlueWillow.com.
media contact
Christine Rose Jutras
TelMed’s strategy
908.947.0500×719
kristin.jutras@tmstrat.com
